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Long noncoding RNAs (lncRNAs) play important roles in human diseases including vascular disease. Given the large number 
of lncRNAs, however, whether the majority of them are associated with vascular disease remains unknown. For this purpose, 
here we present a genomic location based bioinformatics method to predict the lncRNAs associated with vascular disease. We 
applied the presented method to globally screen the human lncRNAs potentially involved in vascular disease. As a result, we 
predicted 3043 putative vascular disease associated lncRNAs. To test the accuracy of the method, we selected 10 lncRNAs 
predicted to be implicated in proliferation and migration of vascular smooth muscle cells (VSMCs) for further experimental 
validation. The results confirmed that eight of the 10 lncRNAs (80%) are validated. This result suggests that the presented 
method has a reliable prediction performance. Finally, the presented bioinformatics method and the predicted vascular disease 
associated lncRNAs together may provide helps for not only better understanding of the roles of lncRNAs in vascular disease 
but also the identification of novel molecules for the diagnosis and therapy of vascular disease. 
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In recent years, a surprising finding in the analysis of hu-
man transcriptome is that mRNAs only account for a small 
portion of the genome transcripts [1]. The majority of the 
human genome transcripts are noncoding RNAs, especially, 
long noncoding RNAs (lncRNAs) [2]. Historically, people 
often argue against the functionality of lncRNAs [3] be-
cause they normally tend to show low cross-species con-
servation, low expression levels and high tissue specificity. 
Recently, however, increasing evidence has suggested that a 
number of lncRNAs have important and diverse functions 
[4]. Therefore, it will be no surprise the dysfunction of 
lncRNAs is associated with a wide spectrum of disease, 
including cardiovascular disease [5] and cancer [6]. Ac-
cording to the statistics of the long noncoding RNA disease 
database (LncRNADisease, http://www.cuilab.cn/lncrnad- 
isease) [7], more than 200 diseases were reported to be as-
sociated with lncRNAs and more than 250 lncRNAs were 
reported to have roles in disease. Therefore, it is believed 
that lncRNAs are becoming a large class of novel molecules 
for disease diagnosis and therapy [8]. Vascular disease rep-
resents one class of serious disease that causes lethal death 
in the world [9]. Given the large number of lncRNAs, how-
ever, the relationship between the majority of lncRNAs and 
 Li JW, et al.   Sci China Life Sci   August (2014) Vol.57 No.8 853 
human disease including vascular disease remains unknown. 
Therefore, it is increasingly emergent and important to 
identify the roles of lncRNAs in vascular disease by devel-
oping bioinformatics methods.  
For the bioinformatics methods to predict novel lncRNA- 
disease associations, we previously presented a genomic 
location based bioinformatics method [7]. Moreover, two 
bioinformatics methods based on co-expression of lncRNA 
and protein-coding genes were presented for cancer [10] 
and human disease [11], respectively. In addition, a method 
of Laplacian Regularized Least Squares for lncRNA-disease 
association (LRLSLDA) based on data from the Lnc- 
RNADisease database and lncRNA expression profile was 
developed [12]. More recently, a network based analysis of 
lncRNA-disease association data in the LncRNADisease 
database revealed a number of regular patterns between 
lncRNAs and disease [13], suggesting that it is feasible to 
predict novel lncRNA-disease associations. Indeed, in the 
same study, the authors developed a network-based method 
to predict novel lncRNA-disease associations [13]. These 
studies and the presented bioinformatics methods together 
provide great helps in understanding the roles of lncRNAs 
in human disease and in finding novel lncRNA-disease as-
sociations. Of course, limitations exist in the above studies. 
For example, the genomic location based method used a 
genomic distance of 2 kb as the cutoff to finding the neigh-
bor genes of an lncRNA. Moreover, the original method 
only focused on disease-associated genes but neglected dis-
ease-associated gene ontology (GO) and gene mutation (e.g., 
SNPs). Comprehensive analysis of lncRNA SNPs has 
showed that SNPs in lncRNAs could contribute to disease 
susceptibility [14]. For the co-expression based methods, 
only a small number of lncRNAs have matched tissues with 
protein-coding genes and lncRNAs does not always have 
similar function with their co-expressed protein-coding 
genes. In addition, the lncRNA-disease network methods 
only focus on a limited number of lncRNAs (~260) con-
tained in the LncRNADisease database and cannot be ap-
plied to the majority of human lncRNAs. Therefore, more 
methods are emergently needed. Here, we focus on vascular 
disease and improved the genomic location based method in 
two aspects. One is that we extended the genomic distance 
to 50 kb, which is suggested to define miRNA clusters in 
the field of miRNAs, another class of noncoding RNAs. It is 
known that the miRNAs in one cluster often have similar 
expression, functions [15], and disease [16]. That is, we 
obtained vascular function associated genes first and then 
identified the lncRNAs within the regions of 50 kb from any 
of the vascular disease genes. In addition, we considered the 
vascular related GO terms and vascular disease related 
SNPs. Together, these lncRNAs are considered to be vas-
cular disease associated lncRNAs. Finally, to evaluate the 
accuracy of the predictions, we randomly select 10 
lncRNAs predicted to be associated with VSMC prolifera-
tion and migration for further biological experiment valida-
tion. As a result, we confirmed that the prediction has a high 
accuracy.  
1  Materials and methods 
1.1  The genomic data used in this study 
We downloaded the genomic location data of 32108 human 
lncRNAs from the LNCipedia database [17] (http://www. 
lncipedia.org/ ). We downloaded the data of gene-disease 
from the GAD database [18] (http://geneticassociationdb. 
nih. gov/). We downloaded the GO from NCBI and disease 
SNPs from the NHGRI GWAS Catalog [19] (http://www. 
genome.gov/gwastudies/). We downloaded the genomic 
location data of reference genes from UCSC [20] (http:// 
genome.ucsc.edu/).  
1.2  The flowchart to predict vascular disease associat-
ed lncRNAs 
As shown in Figure 1, we manually extracted vascular dis-
ease associated genes from the GAD dataset and vascular 
disease associated SNPs from the NHGRI GWAS Catalog 
dataset. We then used an in-house java program to extract 
vascular related GO terms using expert knowledge com-
bined with the following keywords, angiogenesis, angio-
statin, arterial, artery, blood, circulation, vascular, vasculo-
genesis, vasoactive, vasoconstriction, vasodilation, vasomo-
tion, vasopressin, VEGF, vein, and vessel. We next identi-
fied the lncRNAs that are within 50 kb from genes associ-
ated with vascular disease related genes and genes associ-
ated vascular related GO terms. We also identified the 
lncRNAs that host vascular related SNPs. Together we con-
sidered these lncRNAs as putative vascular disease associ-
ated lncRNAs.  
1.3  The model of VSMC proliferation and migration 
VSMCs are highly differentiated cells, but they can undergo 
phenotypic switch from contractile to dedifferentiated phe-
notype such as synthetic, inflammatory and osteo/     
 
 
Figure 1  Flowchart of the genomic location based bioinformatics method 
for the prediction of novel lncRNA-vascular disease associations.  
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chondrocytic phenotype in response to the change of extra- 
cellular matrix. VSMCs’ phenotypic transition plays a criti-
cal role in angiogenesis and restenosis [21]. During this 
process, various growth factors and cytokines such as plate-
let-derived growth factor-BB (PDGF-BB), interleukin-1, 
tumor necrosis factor α (TNF-α) and fibroblast growth fac-
tor (FGF) are markedly increased [22]. PDGF-BB and its 
signaling is a key regulator to mediate VSMC proliferation 
and migration. Inflammatory cytokine TNF-α is powerful to 
promote the secretion of multiple chemokines of VSMCs 
and regulate VSMC proliferation and migration in aortic 
wall injury site. Transcriptional activation of VSMCs mark-
er genes was markedly suppressed by using PDGF-BB and 
TNF-α treatment with primary VSMCs [22,23]. 
Recombinant tumor necrosis factors (TNF-α and 
PDGF-BB) were purchased from Peprotech Ltd. (Rocky 
Hill, USA). VSMCs were isolated from the thoracic aortic 
arteries of Sprague-Dawley rats (body weight 150180 g) as 
described previously [24] and cells at passages 48 were 
used in all experiments. 
1.4  Quantitative real-time PCR analysis 
To test the accuracy of the presented method, here we se-
lected 10 lncRNAs predicted to be associated with VSMC 
proliferation and migration for further experiment validation. 
We used quantitative real-time PCR analysis to evaluate 
whether the predicted lncRNAs are deregulated in the 
treated VSMCs. Real-time PCR amplification involved use 
of an Mx3000 Multiplex Quantitative PCR System (Strata-
gene Corp, USA) and Eva Green reagent normalized to that 
of the internal control β-actin. The 10 candidate lncRNAs 
and their primer sequences of target genes are listed in Ta-
ble 1. All amplification reactions were carried out over 40 
cycles (an initial stage of 7 min at 94°C, then a three-step 
program of 30 s at 94°C, 30 s at 60°C and 30 s at 72°C) and 
were performed in duplicate.  
2  Results 
2.1  Putative vascular disease associated lncRNAs 
The predicted total vascular disease associated lncRNAs, 
their sequence, the associated disease, GO terms, and SNPs 
are available at the download page of the LncRNADisease 
database (http://www.cuilab.cn/lncrnadisease). There are 
2983 lncRNAs, 107 lncRNAs, and 72 lncRNAs in the 
GAD-based predictions, the GO-based predictions, and the 
SNP-based predictions, respectively. As shown in Figure 2, 
all of the 107 GAD-based predictions are included in the 
GO-based predictions, whereas only 12 of the SNP-based 
predictions are included in the GO-based predictions. There 
is no overlap between the GAD-based predictions and the 
SNP-based predictions.  
Table 1  The 10 candidate lncRNAs and their primers for qRT-PCR vali-
dation experiments 







































Figure 2  A pie chart for the distribution of predicted vascular disease 
associated lncRNAs based on the three types (GO-based, GAD-based, and 
SNP-based) of information. 
It will be interesting to find whether some known vascu-
lar disease associated lncRNAs are successfully predicted 
by our method. For this purpose, we first curated the known 
vascular disease associated lncRNAs reported in previous 
studies [2527]. They are Lnc-Ang362, eNOS-AS, TIE-AS, 
MALAT1, and ANRIL. We then matched these lncRNAs 
with the lncRNAs predicted to be associated with vascular 
disease. As a result, three (15 antisense transcripts close   
to eNOS, lnc-CDK5-1:1, lnc-CDK5-2:1lnc-CDK5-2:14; 
three antisense transcripts close to TIE, lnc-ELOVL1-1:1, 
lnc-ELOVL1-1:2, and lnc-ELOVL1-1:3; 16 transcripts of 
ANRIL, lnc-MTAP-1:1lnc-MTAP-1:16) of the five lnc- 
RNAs were found, suggesting that these lncRNAs were 
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successfully predicted. For the two lncRNAs that were not 
predicted, Lnc-Ang362 was not included in the lncRNA 
sequence database (LNCipedia) used in this study. For 
MALAT1, its neighboring gene, SCYL1, is not a known vas-
cular-related gene based on GAD and GO datasets. Therefore, 
these two genes were not predicted to be associated with 
vascular diseases by this method. This result suggests that the 
presented method has reliable prediction accuracy. 
2.2  Validation of putative lncRNAs associated VSMCs 
proliferation and migration 
To evaluate the accuracy of the predictions, we randomly 
selected 10 lncRNAs associated with VSMCs proliferation 
and migration for further validation by biological experi-
ments. For this purpose, here we built two cell models, 
VSMCs treated by PDGF-BB and VSMCs treated by 
TNF-α. We next used qRT-PCR to evaluate whether the 
candidate lncRNAs are deregulated in the treated cells 
compared with the untreated ones. As a result, we found 
that 70% (7/10) of the candidate lncRNAs showed signifi-
cant deregulation (P<0.05) in the PDGF-BB treated VSMCs 
(Figure 3). Moreover, 50% (5/10) of the candidate lncRNAs 
showed significant deregulation (P<0.05) in the TNF-α 
treated VSMCs (Figure 4). Together 80% of the candidate 
lncRNAs are significantly deregulated. The results suggest 
that these putative lncRNAs could be indeed involved in 
VSMCs proliferation and migration, which further suggests 
that the presented method has a reliable accuracy. Moreover, 
by GO-based method, we know that all of the eight 
lncRNAs are putatively involved in blood vessel remodel-
ing, blood vessel morphogenesis, artery morphogenesis, and 
blood vessel development. 
3  Discussion 
lncRNAs represent one large class of important noncoding 
molecules, which play critical roles in human diseases. 
Vascular disease is one class of serious disease that leads to 
lethal death in the world. Therefore, it is increasingly emer-
gent and important to rapidly identify lncRNAs that are 
implicated in vascular disease. In this study, we presented a 
simple genomic location based in-silico method to predict 
novel associations of lncRNAs and vascular disease. An 
independent biological experiment confirmed that the pre-
sented method has a reliable accuracy. Of course, limita-
tions exist in the current method. For example, not all of the 
lncRNAs have at least one neighbor gene within 50 kb dis-
tance. Moreover, lncRNAs are not always functional- 
 
 
Figure 3  Validation results of the 10 candidate lncRNAs associated with VSMC proliferation and migration in the PDGF-BB treated VSMCs. * represents 
significance (P<0.05). 
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Figure 4  Validation results of the 10 candidate lncRNAs associated with VSMC proliferation and migration in the TNF-α treated VSMCs. * represents 
significance (P<0.05). 
ly related with their neighbor genes. In addition, no statisti- 
cal tests were used in the current method. Thus, the method 
seems to be less quantitative. Although limitations exist, we 
believe that the presented method and the predicted vascular 
disease associated lncRNAs provide researchers valuable 
resources for not only better understanding the roles of 
lncRNAs in vascular disease but also identifying novel po-
tential biomarkers and drug targets for vascular disease di-
agnosis and therapy.  
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